Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Depreciation Expense (2016 - 2020)

Ani Pharmaceuticals' Depreciation Expense history spans 9 years, with the latest figure at $1.3 million for Q4 2020.

  • On a quarterly basis, Depreciation Expense rose 8.33% to $1.3 million in Q4 2020 year-over-year; TTM through Dec 2020 was $4.9 million, a 6.52% increase, with the full-year FY2025 number at $8.9 million, up 20.27% from a year prior.
  • Depreciation Expense hit $1.3 million in Q4 2020 for Ani Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over the last five years, Depreciation Expense for ANIP hit a ceiling of $1.3 million in Q4 2020 and a floor of $200000.0 in Q1 2016.
  • Historically, Depreciation Expense has averaged $680000.0 across 5 years, with a median of $500000.0 in 2018.
  • Biggest five-year swings in Depreciation Expense: changed 0.0% in 2016 and later soared 300.0% in 2019.
  • Tracing ANIP's Depreciation Expense over 5 years: stood at $200000.0 in 2016, then soared by 50.0% to $300000.0 in 2017, then skyrocketed by 166.67% to $800000.0 in 2018, then soared by 50.0% to $1.2 million in 2019, then increased by 8.33% to $1.3 million in 2020.
  • Business Quant data shows Depreciation Expense for ANIP at $1.3 million in Q4 2020, $1.2 million in Q3 2020, and $1.2 million in Q2 2020.